Enrico Ferro, MD
@enricoferroMD
Followers
1K
Following
2K
Media
145
Statuses
949
🇮🇹 Cardiology & EP Fellow @BIDMCHealth at Harvard Medical School | Graduate of @BrighamWomens IM, @HarvardMed and @Yale | Member of @Rotary. Opinions my own.
Boston, MA
Joined January 2018
🚩Excited to be selected as one of the 2025 @CardioBusiness "Forty under 40"! I am grateful to be recognized in this great group of cardiologists, executives, and entrepreneurs who are making a major impact on the world of cardiovascular health: https://t.co/8F4oOCKgUJ
1
5
32
Thank you @TCTMD for covering our recently launched @worldheartfed Roadmap on Polypills to prevent and treat cardiovascular disease!
The @worldheartfed is pushing for wider adoption of polypills for CVD prevention worldwide. Evidence on its benefits continue to be solid, but actual usage remains low, according to @enricoferroMD. https://t.co/npwrEO0P7h
1
0
4
Thank you @TCTMD for covering our @worldheartfed Roadmap on the #CVD polypill. Despite better efficacy & cost-effectiveness this technology is not being adopted. A multi-stakeholder collaboration is needed to align on the vision and improve outcomes. https://t.co/QHTkfkhmPs
tctmd.com
The clinical evidence is solid, but so far polypills have not gained traction. Experts want that to change.
0
1
2
Special thanks to @worldheartfed co-author @satheesh_gautam, chairs Drs. Tom Gaziano, @adriannakmurphy , Habib Gamra and the rest of the wonderful team Pablo Perel, Mark Huffman, Pedro Ordunez, @LanaRaspail for this collaboration - stay tuned for more on #CVD polypills!
0
1
3
Last (but most important), we analyze barriers to implementation across three domains: availability, affordability & adoption. In each case, we describe both current obstacles and propose practical solutions to overcome them, and promote widespread adoption of the #CVD polypill.
1
2
2
Next, we provide in-depth analyses of the large cardiovascular outcomes trials for primary & secondary #CVD prevention (HOPE-3, Poly-Iran, TIPS-3, & SECURE) and resulting meta-analyses, which consistently show better efficacy and cost-effectiveness, compared to individual drugs.
1
1
1
First, we cover the history behind the polypill innovation for #CVD, since its ideation in 2000 and through the several #RCT that showed significant improvement in medication adherence ➡️ risk factor control (#Hypertension, #cholesterol) ➡️ reduction in death and adverse events.
1
1
1
#ESCCongress #WCCardio 2025 in #Madrid: excited to launch the @worldheartfed "Roadmap on Single Pill Combination Therapies" for primary & secondary prevention of #CVD #Hypertension #cholesterol, which were included in the 2023 @WHO Essential Medicine List: https://t.co/2UBJR8jWd8
1
7
18
#ESCcongress #wccardio 2025 in Madrid: are you interested in polypill to prevent and treat #CVD like #hypertension & #cholesterol? Join us tomorrow at 12:30 PM (Exchange Area, Hall 9) for the launch of the @worldheartfed Roadmap on Single Pill Combination - see you there! 💊❤️
0
1
13
CV procedures are increasingly migrating into non-hospital procedural centers. What is driving this shift? What are the implications for care quality and access? We address these questions and more below. With this inimitable team @rwyeh @rkwadhera @enricoferroMD
CV care shifting to nonhospital settings presents an important opportunity to assess & improve care access, quality & patient experience, but will require a concerted effort to advance registry data collection @katerinadangas @rwyeh et al in @JACCJournals
https://t.co/vyjqt8OObO
1
8
36
CV care shifting to nonhospital settings presents an important opportunity to assess & improve care access, quality & patient experience, but will require a concerted effort to advance registry data collection @katerinadangas @rwyeh et al in @JACCJournals
https://t.co/vyjqt8OObO
0
0
13
5) Lead extraction + tricuspid intervention did not significantly worsen peri-procedural outcomes at 30 days (vs TV intervention alone). These data should reassure patients & physicians to cautiously deploy lead extraction in this vulnerable population, if clinically indicated.
0
0
0
3) Lead extraction was performed in a minority of these patients (∼20%); surprisingly, CIEDs were re-implanted in only ∼30% of the cases. 4) Over 55% of extracted patients had a clinical indication for extraction, most often endocarditis.
1
0
0
2) Patients CIEDs with represent a sizable minority (∼10%) of all patients undergoing tricuspid valve interventions. They tend to be older & with more comorbitidities, which raises concerns for higher procedural risk.
1
0
0
1) We studied the largest population to date of >2,500 Medicare patients with pre-existing pacemakers/defibrillators (i.e. CIEDs) who underwent tricuspid valve interventions.
1
0
0
Thank you @HeartRhythmTV & @HRSonline for covering our recent study on the safety of concomitant lead extraction and tricuspid valve interventions. Full interview is available here: https://t.co/5C1I5tTPzO See also @TCTMD article at: https://t.co/RdnGnew4VM What did we find?
tctmd.com
Complications weren’t more common when leads were extracted. Yet there’s also the option of “jailing” leads instead.
NEW Abstract Spotlight from HRS 2025: #HRStv host @OliverMonfredi sat down with @enricoferroMD to discuss Practice Patterns and Clinical Outcomes for Tricuspid Valve Interventions among Medicare Patients with Cardiac Implantable Electronic Devices in the United States. See the
1
2
13
New algorithm for WPW AP localization. Looks better than all prior algorithms and pretty easy to follow. @hrs_journal
https://t.co/rnComBUeNh
1
82
264
Congratulations @rwyeh @hectortamezmd @gyfjiang on the @SCAI live case from @BidmcCvi - what an incredible team ready for action!
We are ready to go live from @BidmcCvi to @SCAI!! See you all in a minute. #scai25 @hectortamezmd @EricSecemskyMD @ziadalinyc @FaroucJaffer @JDawnAbbott1 @BinitaShahMD
0
0
10
Our new @AnnalsofIM study finds ⬆ uninsured rates among working-age US adults - with ⬇️Medicaid & employer-based coverage - 1-year after the end of the continuous enrollment provision on March 2023 https://t.co/vywP0cy41w Led by @lucas_marinacci w/ @LiuMichaelON @joefigs2
0
0
3
These data should reassure patients and physicians to cautiously deploy lead extraction in this vulnerable population, especially if clinically indicated. Thank you @EricSecemskyMD, @ZimetbaumP, @rwyeh @SmithBIDMC for the great support in this study!
0
0
2
In the largest analysis to date (N=2,500), we found that concomitant lead extraction + TV intervention did not significantly worsen outcomes at 30 days. Extraction was performed in ∼20% of cases, and >55% of extracted patients had a clinical indication, most often endocarditis.
1
0
2